Genius Sports Limited (NYSE: GENI) stock jumped 7.49% on Monday to $4.45 against a previous-day closing price of $4.14. With 1.3 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.89 million shares. During the session, the Internet Content & Information company that operates in wider Communication Services sector, reached to the highest price of $4.6200 whereas the lowest price it dropped to was $4.1600. The 52-week range on GENI shows that it touched its highest point at $7.09 and its lowest point at $2.20 during that stretch. It currently has a 1-year price target of $7.75.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GENI was up-trending over the past week, with a rise of 1.37%, but this was up by 29.36% over a month. Three-month performance surged to 6.71% while six-month performance rose 73.15%. The stock lost -33.38% in the past year, while it has gained 24.65% so far this year. A look at the trailing 12-month EPS for GENI yields -0.61 with Next year EPS estimates of -0.30. For the next quarter, that number is -0.11. This implies an EPS growth rate of 90.60% for this year and 18.90% for next year.
Float and Shares Shorts:
At present, 200.14 million GENI shares are outstanding with a float of 112.61 million shares on hand for trading. On Oct 13, 2022, short shares totaled 4.91 million, which was 2.25% higher than short shares on Sep 14, 2022. In addition to Mr. Mark Locke as the firm’s Co-Founder, CEO & Director, Mr. Nicholas Taylor serves as its Chief Financial Officer.
Through their ownership of 38.78% of GENI’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 9.91% of GENI, in contrast to 25.97% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in GENI with 9.37% of the stake, Caledonia holds 18,559,335 shares worth 18,559,335. A second-largest stockholder of GENI, Granahan Investment Management, L, holds 9,256,521 shares, controlling over 4.67% of the firm’s shares. Nikko Asset Management Americas, is the third largest shareholder in GENI, holding 5,295,697 shares or 2.67% stake. With a 2.44% stake in GENI, the ARK Next Generation Internet ETF is the largest stakeholder. A total of 4,831,600 shares are owned by the mutual fund manager. The MFS New Discovery Fund, which owns about 1.30% of GENI stock, is the second-largest Mutual Fund holder. It holds 2,578,078 shares valued at 9.2 million. Granahan Funds Plc – US Focused G holds 0.58% of the stake in GENI, owning 1,152,644 shares worth 4.11 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GENI since 8 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With GENI analysts setting a high price target of $10.00 and a low target of $5.00, the average target price over the next 12 months is $7.75. Based on these targets, GENI could surge 124.72% to reach the target high and rise by 12.36% to reach the target low. Reaching the average price target will result in a growth of 74.16% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. GENI will report FY 2022 earnings on 03/08/2024. Analysts have provided yearly estimates in a range of -$0.26 being high and -$0.44 being low. For GENI, this leads to a yearly average estimate of -$0.37. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Genius Sports Limited surprised analysts by $0.04 when it reported -$0.04 EPS against a consensus estimate of -$0.08. The surprise factor in the prior quarter was $0.07. Based on analyst estimates, the high estimate for the next quarter is $0.01 and the low estimate is -$0.17. The average estimate for the next quarter is thus -$0.11.
Summary of Insider Activity:
Insiders traded GENI stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.